This integrated approach synergizes Artificial Intelligence (AI) with DNA-encoded library (DEL) screening. By leveraging AI to analyze DEL data, machine learning models guide lead compound design, multi-target selectivity optimization, and drug-likeness enhancement, thereby accelerating the development of innovative small-molecule therapeutics.